Literature DB >> 23474117

Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer.

John J Coen1, Jonathan J Paly, Andrzej Niemierko, Donald S Kaufman, Niall M Heney, Daphne Y Spiegel, Jason A Efstathiou, Anthony L Zietman, William U Shipley.   

Abstract

PURPOSE: Selective bladder preservation by use of trimodality therapy is an established management strategy for muscle-invasive bladder cancer. Individual disease features have been associated with response to therapy, likelihood of bladder preservation, and disease-free survival. We developed prognostic nomograms to predict the complete response rate, disease-specific survival, and likelihood of remaining free of recurrent bladder cancer or cystectomy. METHODS AND MATERIALS: From 1986 to 2009, 325 patients were managed with selective bladder preservation at Massachusetts General Hospital (MGH) and had complete data adequate for nomogram development. Treatment consisted of a transurethral resection of bladder tumor followed by split-course chemoradiation. Patients with a complete response at midtreatment cystoscopic assessment completed radiation, whereas those with a lesser response underwent a prompt cystectomy. Prognostic nomograms were constructed predicting complete response (CR), disease-specific survival (DSS), and bladder-intact disease-free survival (BI-DFS). BI-DFS was defined as the absence of local invasive or regional recurrence, distant metastasis, bladder cancer-related death, or radical cystectomy.
RESULTS: The final nomograms included information on clinical T stage, presence of hydronephrosis, whether a visibly complete transurethral resection of bladder tumor was performed, age, sex, and tumor grade. The predictive accuracy of these nomograms was assessed. For complete response, the area under the receiving operating characteristic curve was 0.69. The Harrell concordance index was 0.61 for both DSS and BI-DFS.
CONCLUSIONS: Our nomograms allow individualized estimates of complete response, DSS, and BI-DFS. They may assist patients and clinicians making important treatment decisions.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23474117     DOI: 10.1016/j.ijrobp.2013.01.020

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Muscle-invasive bladder cancer treated with TURB followed by concomitant boost with small reduction of radiotherapy field with or without of chemotherapy.

Authors:  Jadwiga Nowak-Sadzikowska; Tomasz Skóra; Bogumiła Szyszka-Charewicz; Jerzy Jakubowicz
Journal:  Rep Pract Oncol Radiother       Date:  2015-09-29

2.  [Treatment of bladder cancer in the elderly].

Authors:  M Fröhner; H Rübben
Journal:  Urologe A       Date:  2015-04       Impact factor: 0.639

3.  Incidental prostate cancer at the time of cystectomy: the incidence and clinicopathological features in Chinese patients.

Authors:  Jiahua Pan; Wei Xue; Jianjun Sha; Hu Yang; Fan Xu; Hanqing Xuan; Dong Li; Yiran Huang
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

4.  Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival.

Authors:  Cheng-Yen Lee; Kai-Lin Yang; Hui-Ling Ko; Rong-Yau Huang; Pei-Pin Tsai; Ming-Tsun Chen; Yi-Chia Lin; Thomas I-Sheng Hwang; Guang-Dar Juang; Kwan-Hwa Chi
Journal:  Radiat Oncol       Date:  2014-09-24       Impact factor: 3.481

Review 5.  Bladder Preservation for Muscle Invasive Bladder Cancer.

Authors:  Arafat Mirza; Ananya Choudhury
Journal:  Bladder Cancer       Date:  2016-04-27

Review 6.  Biomarkers for Predicting Clinical Outcomes of Chemoradiation-Based Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer.

Authors:  Fumitaka Koga; Kosuke Takemura; Hiroshi Fukushima
Journal:  Int J Mol Sci       Date:  2018-09-15       Impact factor: 5.923

7.  Trimodal therapy in T2-4aN0M0 bladder cancer--How to select the best candidate?

Authors:  Ofer N Gofrit; Amichay Meirovitz; Stephen Frank; Igal Rabinovich; Hemda Luwisch; Vladimir Yutkin; Tzahi Neuman; Guy Hidas; Mordechai Duvdevani; Marc Wygoda
Journal:  Cancer Med       Date:  2020-09-22       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.